Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Drugs - Generic
• Sub-Industry: Pharmaceuticals
• Exchange: NASDAQ
• Symbol: SGNT
• CUSIP: 78669210

Key Metrics:

• Previous Close: $21.76
• 50 Day Moving Average: $21.72
• 200 Day Moving Average: $15.37
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: 29.81
• P/E Growth: 0.00
• Market Cap: $N/A
• Beta: 1.66

Additional Links:

• View SGNT on Google Finance
• View SGNT on Yahoo Finance
• View SGNT's Company Profile on Reuters
• Search for Sagent Pharmaceuticals Inc. on Google

Companies Related to Sagent Pharmaceuticals:

• Johnson & Johnson (NYSE:JNJ)
• Roche Holding AG (OTCMKTS:RHHBY)
• Pfizer (NYSE:PFE)
• Novartis AG (NYSE:NVS)
• Merck & Co. (NYSE:MRK)
• UnitedHealth Group (NYSE:UNH)
• Amgen (NASDAQ:AMGN)
• Medtronic (NYSE:MDT)
• Novo Nordisk A/S (NYSE:NVO)
• Gilead Sciences (NASDAQ:GILD)

Earnings

Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
8/8/2016
5/3/2016	Q1	$0.01	($0.15)	$74.30 million	$67.30 million	View	N/A
2/16/2016	Q415	($0.02)	($0.55)	$78.13 million	$83.10 million	View	Listen
11/3/2015	Q315	($0.07)	$0.01	$73.84 million	$75.20 million	View	N/A
8/4/2015	Q215	$0.05	($0.01)	$83.28 million	$77.30 million	View	N/A
5/5/2015	Q115	$0.04	$0.04	$80.63 million	$82.60 million	View	N/A
2/19/2015	Q414	$0.01	$0.91	$76.20 million	$84.40 million	View	N/A
11/4/2014	Q314	($0.04)	$0.08	$64.01 million	$65.40 million	View	N/A
7/30/2014	Q214	($0.01)	$0.09	$67.14 million	$69.20 million	View	Listen
5/6/2014	Q114	($0.02)	$0.16	$65.66 million	$70.90 million	View	Listen
2/11/2014	Q4	($0.01)	$0.11	$60.25 million	$64.10 million	View	Listen
11/5/2013		($0.03)	$0.10			View	N/A
8/6/2013	Q2 2013		$0.46	$59.27 million	$59.60 million	View	N/A
5/6/2013	Q1 2013	($0.03)	$0.34	$55.31 million	$60.20 million	View	N/A
11/8/2012	Q312	($0.20)	($0.13)	$48.60 million	$49.40 million	View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	$0.06	$0.06	$0.06
Q2 2016	1	($0.19)	($0.19)	($0.19)
Q3 2016	1	$0.19	$0.19	$0.19
Q4 2016	1	$0.35	$0.35	$0.35

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sagent Pharmaceuticals (NASDAQ:SGNT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
4/21/2016	Ventures Fund V L.P. Vivo	Major Shareholder	Sell	2,005	$13.55	$27,167.75
11/4/2015	Ventures Fund V L.P. Vivo	Major Shareholder	Sell	603,177	$15.72	$9,481,942.44
11/3/2015	Vivo Ventures Vi, Llc	Major Shareholder	Sell	67,283	$16.32	$1,098,058.56
11/2/2015	Vivo Ventures Vi, Llc	Major Shareholder	Sell	93,523	$16.87	$1,577,733.01
1/27/2015	Morgan Stanley Investment Mana	Major Shareholder	Sell	78,041	$26.16	$2,041,552.56
1/23/2015	Morgan Stanley Investment Mana	Major Shareholder	Sell	211,883	$25.61	$5,426,323.63
1/21/2015	Morgan Stanley Investment Mana	Major Shareholder	Sell	69,316	$25.23	$1,748,842.68
1/16/2015	Morgan Stanley Investment Mana	Major Shareholder	Sell	125,000	$25.16	$3,145,000.00
1/14/2015	Morgan Stanley Investment Mana	Major Shareholder	Sell	100,000	$25.51	$2,551,000.00
10/8/2014	Robert J Flanagan	Director	Sell	16,000	$31.56	$504,960.00
10/7/2014	Robert J Flanagan	Director	Sell	8,000	$31.15	$249,200.00
9/25/2014	Robert J Flanagan	Director	Sell	16,000	$30.01	$480,160.00
9/24/2014	Robert J Flanagan	Director	Sell	8,000	$30.30	$242,400.00
9/12/2014	Robert J Flanagan	Director	Sell	16,000	$28.30	$452,800.00
9/11/2014	Robert J Flanagan	Director	Sell	8,000	$28.35	$226,800.00
8/28/2014	Robert J Flanagan	Director	Sell	16,000	$27.19	$435,040.00
8/27/2014	Robert J Flanagan	Director	Sell	8,000	$27.30	$218,400.00
8/12/2014	Robert J Flanagan	Director	Sell	16,000	$24.39	$390,240.00
7/31/2014	Robert J Flanagan	Director	Sell	16,000	$25.60	$409,600.00
7/18/2014	Robert J Flanagan	Director	Sell	16,000	$26.18	$418,880.00
7/2/2014	Robert J Flanagan	Director	Sell	16,000	$26.51	$424,160.00
6/18/2014	Robert J Flanagan	Director	Sell	16,000	$23.37	$373,920.00
6/4/2014	Robert J Flanagan	Director	Sell	16,000	$22.17	$354,720.00
5/22/2014	Robert Flanagan	Director	Sell	8,000	$22.02	$176,160.00
2/27/2014	Michael Logerfo	Insider	Sell	2,021	$21.43	$43,310.03
10/3/2013	Morgan Stanley Investment Mana	major shareholder	Sell	47,826	$20.27	$969,433.02
9/26/2013	Morgan Stanley Investment Mana	major shareholder	Sell	67,965	$20.37	$1,384,447.05
9/25/2013	Morgan Stanley Investment Mana	major shareholder	Sell	48,124	$21.30	$1,025,041.20
9/23/2013	Morgan Stanley Investment Mana	major shareholder	Sell	119,557	$21.83	$2,609,929.31
9/19/2013	Morgan Stanley Investment Mana	major shareholder	Sell	88,885	$22.53	$2,002,579.05
9/16/2013	Frank Kung	Director	Sell	1,161,717	$21.25	$24,686,486.25
9/16/2013	Jeffrey Yordon	CEO	Sell	85,813	$20.03	$1,718,834.39
9/16/2013	Vivo Ventures Vi, Llc	major shareholder	Sell	622,700	$21.25	$13,232,375.00
8/12/2013	Lorin Drake	VP	Sell	1,000	$23.69	$23,690.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)

Date	Headline
	Sagent Pharmaceuticals' (SGNT) Overweight Rating Reiterated at Piper Jaffray - DailyQuint (NASDAQ:SGNT) dailyquint.com - September 21 at 11:21 AM
	NWQ Bought 12 New Holdings in 2nd Quarter - Yahoo Sports (NASDAQ:SGNT) sports.yahoo.com - September 16 at 7:00 PM
	NWQ Bought 12 New Holdings in 2nd Quarter (NASDAQ:SGNT) finance.yahoo.com - September 16 at 7:00 PM
	Placing Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Shares Under the Microscope - Post News (NASDAQ:SGNT) www.kentuckypostnews.com - September 8 at 6:57 PM
	Form 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony (NASDAQ:SGNT) www.streetinsider.com - September 1 at 7:13 PM
	Stock in Review: Taking a Closer Look at Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Shares - Post News (NASDAQ:SGNT) www.kentuckypostnews.com - September 1 at 10:28 AM
	Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the ... (NASDAQ:SGNT) www.biomedreports.com - August 30 at 10:37 AM
	Nichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) www.thestreet.com - August 30 at 10:37 AM
	Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) au.finance.yahoo.com - August 29 at 7:14 PM
	SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist (NASDAQ:SGNT) biz.yahoo.com - August 29 at 7:14 PM
	Can Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - August 29 at 11:54 AM
	BRIEF-Nichi-Iko Pharmaceutical fully buys Sagent Pharmaceuticals, Inc. via takeover bid (NASDAQ:SGNT) feeds.reuters.com - August 28 at 10:24 PM
	Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - August 26 at 10:18 AM
	Is it Time to Buy Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? The Consensus Is In - Post News (NASDAQ:SGNT) www.kentuckypostnews.com - August 25 at 12:28 PM
	Investor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed (NASDAQ:SGNT) www.groundreport.com - August 23 at 11:53 AM
	Investor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed - GroundReport (NASDAQ:SGNT) www.groundreport.com - August 22 at 7:17 PM
	Ratings & Crowd Appeal on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Post News (NASDAQ:SGNT) www.kentuckypostnews.com - August 20 at 11:22 AM
	Will Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75 Price Target? - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - August 19 at 7:17 PM
	Analysts See Sales Of $503.34 For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - August 19 at 7:17 PM
	Active Watchful Movers- NetApp, Inc. (NASDAQ:NTAP), AT&T, Inc. (NYSE:T), Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) (NASDAQ:SGNT) www.senecaglobe.com - August 18 at 10:27 AM
	Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter (NASDAQ:SGNT) www.publicnow.com - August 17 at 7:45 PM
	SAGENT PHARMACEUTICALS, INC. Financials (NASDAQ:SGNT) finance.yahoo.com - August 16 at 7:30 PM
	Lawsuit for Investors in Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Against Buyout Filed (NASDAQ:SGNT) www.4-traders.com - August 15 at 7:47 PM
	Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Records An Estimated Annual Sales Mean Of $503.34 - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - August 12 at 7:29 PM
	ETF’s with exposure to Sagent Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:SGNT) www.capitalcube.com - August 12 at 7:29 PM
	Sagent Pharmaceuticals, Inc. :SGNT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:SGNT) www.capitalcube.com - August 10 at 7:54 PM
	Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT) (NASDAQ:SGNT) finance.yahoo.com - August 10 at 7:54 PM
	Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc. (NASDAQ:SGNT) www.streetinsider.com - August 9 at 7:41 PM
	Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) au.finance.yahoo.com - August 9 at 10:37 AM
	SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:SGNT) biz.yahoo.com - August 5 at 7:38 PM
	Shepard Vision, Inc., a Wholly-Owned Subsidiary of … (NASDAQ:SGNT) www.tmcnet.com - August 1 at 7:07 PM
	Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash … (NASDAQ:SGNT) finance.yahoo.com - August 1 at 1:01 PM
	BRIEF-Shepard Vision commences all-cash tender offer of $21.75 net per share to buy shares of Sagent (NASDAQ:SGNT) feeds.reuters.com - August 1 at 11:43 AM
	Investor News: Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) faces Investigation (NASDAQ:SGNT) www.groundreport.com - July 29 at 10:28 AM
	Can Shares Of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75? - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - July 28 at 7:41 PM
	Sapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors (NASDAQ:SGNT) www.publicnow.com - July 28 at 9:28 AM
	Is $21.75 Price Target Attainable For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? - Investor Newswire (NASDAQ:SGNT) www.investornewswire.com - July 22 at 7:09 PM
	Stock Observed in Overbought Territory: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph (NASDAQ:SGNT) presstelegraph.com - July 22 at 7:09 PM
	Sagent Pharmaceuticals Incorporated (NASDAQ:SGNT) Sellers Increased By 21.86% Their Shorts - Press Telegraph (NASDAQ:SGNT) presstelegraph.com - July 22 at 7:09 PM
	INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) finance.yahoo.com - July 22 at 11:48 AM
	Acquisition of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Under Investigation for Investors (NASDAQ:SGNT) www.sbwire.com - July 21 at 7:44 PM
	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors … (NASDAQ:SGNT) finance.yahoo.com - July 20 at 8:18 PM
	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Regarding the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - SGNT (NASDAQ:SGNT) finance.yahoo.com - July 20 at 4:16 PM
	Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:SGNT) www.engelwooddaily.com - July 20 at 10:17 AM
	Sagent Pharmaceuticals (SGNT) Launches Amikacin Sulfate Injection, USP - StreetInsider.com (NASDAQ:SGNT) www.streetinsider.com - July 20 at 10:17 AM
	Analyst's Valuable Buzzers: Medtronic plc (NYSE:MDT) , Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Street Updates (NASDAQ:SGNT) www.streetupdates.com - July 20 at 10:17 AM
	INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information (NASDAQ:SGNT) finance.yahoo.com - July 19 at 2:02 PM
	Trading Performance and Target Watch for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph (NASDAQ:SGNT) presstelegraph.com - July 18 at 3:24 PM
	Stock in Positive Territory for the Quarter: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Engelwood Daily (NASDAQ:SGNT) www.engelwooddaily.com - July 18 at 3:24 PM
	Sagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP - GlobeNewswire (press release) (NASDAQ:SGNT) globenewswire.com - July 18 at 3:24 PM

Social

Sagent Pharmaceuticals (NASDAQ:SGNT) Chart for Sunday, September, 25, 2016